Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Endometrial Neoplasms × talazoparib × Clear all

Phase

Status

Recruiting 2 Withdrawn 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Mesothelioma 1 Endometrial Neoplasms 1 Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 3 NVP-BKM120 2 trastuzumab duocarmazine 1 talazoparib 1 sitravatinib 1 ponatinib 1 mirvetuximab soravtansine 1 lenvatinib 1 dostarlimab 1 dactolisib 1 Trastuzumab 1 Taxes 1 TAS-116 1 Sevoflurane 1 Radiotherapy 1 Propofol 1 Proflavine 1 Polymerase Chain Reaction 1 Paclitaxel 1 PM 01183 1 Methods 1 Metformin 1 Megestrol Acetate 1 Magnetic Resonance Spectroscopy 1 Letrozole 1 Interviews as Topic 1 Gene Expression Profiling 1 FP-1039 1 Educational Status 1 Early Intervention, Educational 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02127151 2021-08-06

PANDA

University College, London

Phase 2 Withdrawn

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡